UK markets closed
  • NIKKEI 225

    29,642.69
    +21.70 (+0.07%)
     
  • HANG SENG

    28,793.14
    -107.69 (-0.37%)
     
  • CRUDE OIL

    63.41
    +0.26 (+0.41%)
     
  • GOLD FUTURES

    1,768.20
    +31.90 (+1.84%)
     
  • DOW

    33,997.44
    +266.55 (+0.79%)
     
  • BTC-GBP

    45,541.83
    -838.89 (-1.81%)
     
  • CMC Crypto 200

    1,379.29
    -1.66 (-0.12%)
     
  • ^IXIC

    14,030.73
    +172.89 (+1.25%)
     
  • ^FTAS

    3,988.72
    +24.05 (+0.61%)
     

Global Machine Tools Industry

ReportLinker
·14-min read

Abstract: - The worst affected industry in this pandemic driven crisis is manufacturing with its complex supply chains, labor intensive processes, and interdependencies. Division of labor, modular manufacturing strategies, outsourcing to reduce costs and increase the efficiency, consistency, and quality of each operations, have made the manufacturing sector most vulnerable amid the lockdown restrictions.

New York, April 07, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Machine Tools Industry" - https://www.reportlinker.com/p05112917/?utm_source=GNW
A revised outlook pegs the global market for machine tools at US$87.4 billion by 2027. An indication of the grim state of affairs is the fact that global manufacturing PMI is already declining and will fall to an estimated all-time low of 35.4 points in 2020 as compared to 53.8 in 2019. This indicates severe contraction of manufacturing activity including new orders, production, employment, supplier deliveries, inventories, customers’ inventories, commodity prices, order backlog, new export orders, and imports. Business investment confidence is tumbling amidst poor demand, falling profits, liquidity crunch and a reeling global economy. The "great lockdown" of 2020 has crushed the global economy and with it the manufacturing sector. The COVID-19 pandemic will have lasting long-term economic, social and political impact. As death tolls continue to rise worldwide with the infections showing no signs of slowing down, a major change in priorities is underway as governments struggle amid the crisis to strengthen their healthcare systems. The pandemic has laid bare the unpreparedness of health systems in countries worldwide. To curb the pandemic, governments have and continue to impose strict lockdowns and ban on all non-essential business operations, thus bringing all economic activity to a virtual halt. SMB manufacturers will be worst affected with over 50% of SMEs voicing uncertainty over their companies’ ability to survive the corona virus-related shutdown.
- As businesses struggle to keep afloat, job cuts and bankruptcies are expected to rise sending millions into unemployment. Unemployment rates are climbing to worrisome levels in both developed and developing economies alike. In the US alone, over 5. 2 million people have filed for unemployment claims over the last 1 month. The economic anxiety among consumers has and continues to rise. Consumers have shifted to online and are spending much lesser than before the pandemic. Social outlook against this background remains grim with households expected witness erosion in wealth. Personal financial outlook, community, economy, job security confidence, purchasing and investment confidence are all tumbling as the human and economic cost of the global pandemic rises. The loss in consumer confidence and erosion of household wealth and discretionary spending will impact virtually every industry and business worldwide. Global merchandize trade is expected to plummet by15% to 30% in the year 2020highlighting the magnitude of disruption. Against this backdrop, it requires very little speculation to measure the impact on manufacturing. In the United States alone over 80% of manufacturers are bracing for losses. The impact will mean crunch on capital resources; workforce layoffs/reduction and loss in productivity; supply chain disruptions; difficulties with funding; and increase in cyber security risks and fraud. Unlike IT services where work is being carried out remotely via internet and cloud platforms, for the manufacturing industry, plant activities and production cannot be carried remotely and therefore remains worst affected. The slower economic activity means reduced demand for industrial and consumer goods and lower manufacturing orders.

- Select Competitors (Total 412 Featured) -

  • Ace Micromatic Group

  • Allied Machine & Engineering Corporation

  • Amada Co, Ltd.

  • Amada Machine Tools America, Inc.

  • Chiron Group SE

  • Dalian Machine Tool Group Corporation

  • DMG Mori Co., Ltd.

  • Doosan Machine Tools Co. Ltd.

  • Electronica Hitech Engineering Pvt. Ltd.

  • FANUC Corporation

  • FANUC America Corporation

  • GF Machining Solutions Management SA

  • Gleason Corporation

  • GROB-WERKE GmbH & Co. KG

  • Hardinge, Inc.

  • Jones & Shipman Hardinge Ltd.

  • Haas Automation, Inc.

  • Hyundai WIA Co. Ltd.

  • JTEKT Corporation

  • Kennametal Inc.

  • Komatsu Ltd.

  • Makino Milling Machine Co. Ltd.

  • Okuma Corporation

  • Otto Bihler Maschinenfabrik GmbH & Co. KG

  • Sandvik AB

  • Sandvik Coromant

  • Schuler AG

  • Shanghai Machine Tool Works Ltd.

  • Shape Technologies Group

  • Sodick

  • Spinner Machine Tools GmbH

  • TAJMAC-ZPS, a.s.

  • Trumpf Group

  • Walter AG

  • Yamazaki Mazak Corporation




Read the full report: https://www.reportlinker.com/p05112917/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Meningococcal
Vaccines by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2027 and % CAGR

Table 2: World Historic Review for Meningococcal Vaccines by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2017 and
% CAGR

Table 3: World 15-Year Perspective for Meningococcal Vaccines
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2018 & 2027

Table 4: World Current & Future Analysis for Polysaccharide
Meningococcal Vaccines by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2018 through 2027 and % CAGR

Table 5: World Historic Review for Polysaccharide Meningococcal
Vaccines by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017 and % CAGR

Table 6: World 15-Year Perspective for Polysaccharide
Meningococcal Vaccines by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2012, 2018 & 2027

Table 7: World Current & Future Analysis for Conjugate
Meningococcal Vaccines by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2018 through 2027 and % CAGR

Table 8: World Historic Review for Conjugate Meningococcal
Vaccines by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017 and % CAGR

Table 9: World 15-Year Perspective for Conjugate Meningococcal
Vaccines by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2018 & 2027

Table 10: World Current & Future Analysis for Combination
Meningococcal Vaccines by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2018 through 2027 and % CAGR

Table 11: World Historic Review for Combination Meningococcal
Vaccines by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017 and % CAGR

Table 12: World 15-Year Perspective for Combination
Meningococcal Vaccines by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2012, 2018 & 2027

Table 13: World Current & Future Analysis for Meningococcal B
Vaccines by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2027 and % CAGR

Table 14: World Historic Review for Meningococcal B Vaccines by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2017 and
% CAGR

Table 15: World 15-Year Perspective for Meningococcal B
Vaccines by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2018 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 16: USA Current & Future Analysis for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027 and
% CAGR

Table 17: USA Historic Review for Meningococcal Vaccines by
Type - Polysaccharide Meningococcal Vaccines, Conjugate
Meningococcal Vaccines, Combination Meningococcal Vaccines and
Meningococcal B Vaccines Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017 and %
CAGR

Table 18: USA 15-Year Perspective for Meningococcal Vaccines by
Type - Percentage Breakdown of Value Sales for Polysaccharide
Meningococcal Vaccines, Conjugate Meningococcal Vaccines,
Combination Meningococcal Vaccines and Meningococcal B Vaccines
for the Years 2012, 2018 & 2027

CANADA
Table 19: Canada Current & Future Analysis for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027 and
% CAGR

Table 20: Canada Historic Review for Meningococcal Vaccines by
Type - Polysaccharide Meningococcal Vaccines, Conjugate
Meningococcal Vaccines, Combination Meningococcal Vaccines and
Meningococcal B Vaccines Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017 and %
CAGR

Table 21: Canada 15-Year Perspective for Meningococcal Vaccines
by Type - Percentage Breakdown of Value Sales for
Polysaccharide Meningococcal Vaccines, Conjugate Meningococcal
Vaccines, Combination Meningococcal Vaccines and Meningococcal
B Vaccines for the Years 2012, 2018 & 2027

JAPAN
Table 22: Japan Current & Future Analysis for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027 and
% CAGR

Table 23: Japan Historic Review for Meningococcal Vaccines by
Type - Polysaccharide Meningococcal Vaccines, Conjugate
Meningococcal Vaccines, Combination Meningococcal Vaccines and
Meningococcal B Vaccines Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017 and %
CAGR

Table 24: Japan 15-Year Perspective for Meningococcal Vaccines
by Type - Percentage Breakdown of Value Sales for
Polysaccharide Meningococcal Vaccines, Conjugate Meningococcal
Vaccines, Combination Meningococcal Vaccines and Meningococcal
B Vaccines for the Years 2012, 2018 & 2027

CHINA
Table 25: China Current & Future Analysis for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027 and
% CAGR

Table 26: China Historic Review for Meningococcal Vaccines by
Type - Polysaccharide Meningococcal Vaccines, Conjugate
Meningococcal Vaccines, Combination Meningococcal Vaccines and
Meningococcal B Vaccines Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017 and %
CAGR

Table 27: China 15-Year Perspective for Meningococcal Vaccines
by Type - Percentage Breakdown of Value Sales for
Polysaccharide Meningococcal Vaccines, Conjugate Meningococcal
Vaccines, Combination Meningococcal Vaccines and Meningococcal
B Vaccines for the Years 2012, 2018 & 2027

EUROPE
Table 28: Europe Current & Future Analysis for Meningococcal
Vaccines by Geographic Region - France, Germany, Italy, UK and
Rest of Europe Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2018 through 2027 and % CAGR

Table 29: Europe Historic Review for Meningococcal Vaccines by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017 and % CAGR

Table 30: Europe 15-Year Perspective for Meningococcal Vaccines
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2012, 2018 & 2027

Table 31: Europe Current & Future Analysis for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027 and
% CAGR

Table 32: Europe Historic Review for Meningococcal Vaccines by
Type - Polysaccharide Meningococcal Vaccines, Conjugate
Meningococcal Vaccines, Combination Meningococcal Vaccines and
Meningococcal B Vaccines Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017 and %
CAGR

Table 33: Europe 15-Year Perspective for Meningococcal Vaccines
by Type - Percentage Breakdown of Value Sales for
Polysaccharide Meningococcal Vaccines, Conjugate Meningococcal
Vaccines, Combination Meningococcal Vaccines and Meningococcal
B Vaccines for the Years 2012, 2018 & 2027

FRANCE
Table 34: France Current & Future Analysis for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027 and
% CAGR

Table 35: France Historic Review for Meningococcal Vaccines by
Type - Polysaccharide Meningococcal Vaccines, Conjugate
Meningococcal Vaccines, Combination Meningococcal Vaccines and
Meningococcal B Vaccines Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017 and %
CAGR

Table 36: France 15-Year Perspective for Meningococcal Vaccines
by Type - Percentage Breakdown of Value Sales for
Polysaccharide Meningococcal Vaccines, Conjugate Meningococcal
Vaccines, Combination Meningococcal Vaccines and Meningococcal
B Vaccines for the Years 2012, 2018 & 2027

GERMANY
Table 37: Germany Current & Future Analysis for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027 and
% CAGR

Table 38: Germany Historic Review for Meningococcal Vaccines by
Type - Polysaccharide Meningococcal Vaccines, Conjugate
Meningococcal Vaccines, Combination Meningococcal Vaccines and
Meningococcal B Vaccines Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017 and %
CAGR

Table 39: Germany 15-Year Perspective for Meningococcal
Vaccines by Type - Percentage Breakdown of Value Sales for
Polysaccharide Meningococcal Vaccines, Conjugate Meningococcal
Vaccines, Combination Meningococcal Vaccines and Meningococcal
B Vaccines for the Years 2012, 2018 & 2027

ITALY
Table 40: Italy Current & Future Analysis for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027 and
% CAGR

Table 41: Italy Historic Review for Meningococcal Vaccines by
Type - Polysaccharide Meningococcal Vaccines, Conjugate
Meningococcal Vaccines, Combination Meningococcal Vaccines and
Meningococcal B Vaccines Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017 and %
CAGR

Table 42: Italy 15-Year Perspective for Meningococcal Vaccines
by Type - Percentage Breakdown of Value Sales for
Polysaccharide Meningococcal Vaccines, Conjugate Meningococcal
Vaccines, Combination Meningococcal Vaccines and Meningococcal
B Vaccines for the Years 2012, 2018 & 2027

UNITED KINGDOM
Table 43: UK Current & Future Analysis for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027 and
% CAGR

Table 44: UK Historic Review for Meningococcal Vaccines by Type -
Polysaccharide Meningococcal Vaccines, Conjugate
Meningococcal Vaccines, Combination Meningococcal Vaccines and
Meningococcal B Vaccines Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017 and %
CAGR

Table 45: UK 15-Year Perspective for Meningococcal Vaccines by
Type - Percentage Breakdown of Value Sales for Polysaccharide
Meningococcal Vaccines, Conjugate Meningococcal Vaccines,
Combination Meningococcal Vaccines and Meningococcal B Vaccines
for the Years 2012, 2018 & 2027

REST OF EUROPE
Table 46: Rest of Europe Current & Future Analysis for
Meningococcal Vaccines by Type - Polysaccharide Meningococcal
Vaccines, Conjugate Meningococcal Vaccines, Combination
Meningococcal Vaccines and Meningococcal B Vaccines -
Independent Analysis of Annual Sales in US$ Million for the
Years 2018 through 2027 and % CAGR

Table 47: Rest of Europe Historic Review for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017 and % CAGR

Table 48: Rest of Europe 15-Year Perspective for Meningococcal
Vaccines by Type - Percentage Breakdown of Value Sales for
Polysaccharide Meningococcal Vaccines, Conjugate Meningococcal
Vaccines, Combination Meningococcal Vaccines and Meningococcal
B Vaccines for the Years 2012, 2018 & 2027

ASIA-PACIFIC
Table 49: Asia-Pacific Current & Future Analysis for
Meningococcal Vaccines by Type - Polysaccharide Meningococcal
Vaccines, Conjugate Meningococcal Vaccines, Combination
Meningococcal Vaccines and Meningococcal B Vaccines -
Independent Analysis of Annual Sales in US$ Million for the
Years 2018 through 2027 and % CAGR

Table 50: Asia-Pacific Historic Review for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017 and % CAGR

Table 51: Asia-Pacific 15-Year Perspective for Meningococcal
Vaccines by Type - Percentage Breakdown of Value Sales for
Polysaccharide Meningococcal Vaccines, Conjugate Meningococcal
Vaccines, Combination Meningococcal Vaccines and Meningococcal
B Vaccines for the Years 2012, 2018 & 2027

REST OF WORLD
Table 52: Rest of World Current & Future Analysis for
Meningococcal Vaccines by Type - Polysaccharide Meningococcal
Vaccines, Conjugate Meningococcal Vaccines, Combination
Meningococcal Vaccines and Meningococcal B Vaccines -
Independent Analysis of Annual Sales in US$ Million for the
Years 2018 through 2027 and % CAGR

Table 53: Rest of World Historic Review for Meningococcal
Vaccines by Type - Polysaccharide Meningococcal Vaccines,
Conjugate Meningococcal Vaccines, Combination Meningococcal
Vaccines and Meningococcal B Vaccines Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017 and % CAGR

Table 54: Rest of World 15-Year Perspective for Meningococcal
Vaccines by Type - Percentage Breakdown of Value Sales for
Polysaccharide Meningococcal Vaccines, Conjugate Meningococcal
Vaccines, Combination Meningococcal Vaccines and Meningococcal
B Vaccines for the Years 2012, 2018 & 2027

IV. COMPETITION
Total Companies Profiled: 42
Read the full report: https://www.reportlinker.com/p05112917/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001